A Phase 2/3 interventional study of Bevacizumab in Macular Edema and Diabetic Retinopathy, sponsored by Isfahan Ophthalmology Research Center. Status unknown. Per ClinicalTrials.gov, last updated 2008-06-23.
Sponsored by Isfahan Ophthalmology Research Center · Phase 2/3 and Interventional
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
841 studies on the registry are indexed under Macular Edema; 56 are open to participants now.
Browse Macular Edema studies →This is the only study on the registry with Isfahan Ophthalmology Research Center as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
No study locations are listed for this record.
This study is status unknown, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.